Landiolol - AOP Orphan Pharmaceuticals

Drug Profile

Landiolol - AOP Orphan Pharmaceuticals

Alternative Names: AOP200704; LDLL600; Rapibloc

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AOP Orphan Pharmaceuticals AG
  • Class Antiarrhythmics; Morpholines; Small molecules; Urea compounds
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arrhythmias
  • Phase III Supraventricular tachycardia

Most Recent Events

  • 19 Jun 2017 Landiolol market-licensed to AMOMED Pharma in European Union
  • 19 Jun 2017 Launched for Arrhythmias in Austria (IV)
  • 19 Jun 2017 Launched for Arrhythmias in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top